Company Overview

Hyperfine, Inc. is a medical technology company focused on developing and commercializing portable magnetic resonance imaging (MRI) systems. The company operates within the medical imaging and diagnostic healthcare technology industries, with a specific emphasis on improving access to MRI through lower-cost, point-of-care solutions. Its core product is designed to bring MRI capabilities to settings where traditional fixed MRI systems are impractical due to cost, infrastructure, or space requirements.

The company’s primary revenue driver is the commercialization of its portable MRI system for clinical use, targeting hospitals, emergency departments, intensive care units, and neurological care settings. Hyperfine is uniquely positioned through its use of ultra-low-field MRI technology, which enables mobility, reduced shielding requirements, and lower operational complexity compared to conventional MRI. The company was founded in 2014 and emerged from research efforts aimed at democratizing advanced imaging; it became publicly traded in 2021 following a merger with a special purpose acquisition company (SPAC).

Business Operations

Hyperfine operates primarily through a single operating segment focused on the development, manufacturing, and commercialization of its portable MRI system, marketed under the Swoop® Portable MR Imaging System. Revenue is generated through system sales, service agreements, and related consumables. The company controls proprietary hardware designs, software, and image reconstruction technologies that underpin its low-field MRI platform.

Operations include research and development, regulatory compliance, manufacturing oversight, and direct sales primarily in the United States, with expanding international distribution. Hyperfine works with manufacturing partners rather than owning large-scale production facilities and relies on a direct sales force supplemented by distributors in select international markets. Public disclosures do not indicate material joint ventures; operations are conducted primarily through the parent company and its wholly owned subsidiaries.

Strategic Position & Investments

Hyperfine’s strategy centers on expanding adoption of portable MRI by demonstrating clinical utility, improving image quality through software enhancements, and broadening approved clinical indications. Growth initiatives include increasing hospital penetration, expanding international regulatory approvals, and investing in next-generation product development and artificial intelligence–driven image reconstruction.

The company has invested heavily in research and development rather than pursuing large acquisitions, reflecting its focus on organic growth. Its strategic positioning emphasizes cost reduction, bedside accessibility, and workflow integration as differentiators against incumbent high-field MRI manufacturers. Hyperfine’s activities are concentrated in portable diagnostic imaging rather than a diversified portfolio of unrelated healthcare assets.

Geographic Footprint

Hyperfine is headquartered in Guilford, Connecticut, United States, and derives the majority of its revenue from the United States market. Its systems are deployed across multiple U.S. hospitals and academic medical centers, particularly in neurological and critical care settings.

Internationally, the company has established a presence in parts of Europe, Asia-Pacific, and other select regions through regulatory clearances and distributor relationships. While international revenue remains smaller relative to domestic sales, global expansion is a stated priority, supported by regulatory approvals and clinical collaborations outside the U.S.

Leadership & Governance

Hyperfine was founded by Jonathan Rothberg, who played a key role in the company’s early technological vision and development. The leadership team emphasizes innovation, clinical validation, and expanding access to advanced imaging through disruptive technology.

Key executives include:

• Maria Sainz – President and Chief Executive Officer
• Mark Brown – Chief Financial Officer
• Michael Pugliese – Chief Operating Officer
• Jonathan Rothberg – Founder and Chairman

The company’s governance structure follows standard U.S. public company practices, with a board overseeing strategy, capital allocation, and risk management, and leadership articulating a vision centered on accessibility, affordability, and clinical impact in medical imaging.